Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
Condition(s):Locally Advanced Breast Cancer; Metastatic Breast CancerLast Updated:March 25, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Locally Advanced Breast Cancer; Metastatic Breast CancerLast Updated:March 25, 2024Recruiting
Condition(s):HER2-positive Metastatic Breast Cancer; Locally Advanced HER2 Positive Breast CarcinomaLast Updated:June 12, 2023Recruiting
Condition(s):Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor PositiveLast Updated:December 15, 2023Recruiting
Condition(s):Advanced Breast CancerLast Updated:March 24, 2023Recruiting
Condition(s):Breast Cancer and PregnancyLast Updated:November 18, 2023Recruiting
Condition(s):Breast CancerLast Updated:March 15, 2023Completed
Condition(s):Metastatic Breast CancerLast Updated:November 14, 2023Active, not recruiting
Condition(s):Early Breast CancerLast Updated:July 19, 2023Active, not recruiting
Condition(s):Breast Cancer; Luminal BLast Updated:January 13, 2023Completed
Condition(s):Breast Carcinoma Metastatic to the BoneLast Updated:March 6, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.